Enhancing procedural quality and efficiency of methacholine bronchial challenge tests in patients with suspected cough-variant asthma: a quasi-experimental study utilizing nurse–patient communication and respiratory training - Scorecard - MDSpire
Advertisement
Enhancing procedural quality and efficiency of methacholine bronchial challenge tests in patients with suspected cough-variant asthma: a quasi-experimental study utilizing nurse–patient communication and respiratory training
Clinical Scorecard: Improving the Quality and Efficiency of Methacholine Bronchial Challenge Tests in Individuals with Suspected Cough-Variant Asthma: A Quasi-Experimental Study on Nurse-Patient Communication and Respiratory Training
At a Glance
Category
Detail
Condition
Cough-Variant Asthma
Key Mechanisms
Nurse-patient communication and respiratory training improve procedural quality of MBCT.
Target Population
Adults with suspected cough-variant asthma.
Care Setting
Single-center clinical testing environment.
Key Highlights
Intervention group had a higher first-attempt success rate (75.6% vs. 24.4%).
Shorter in-chamber testing duration in the intervention group (11.85 min vs. 16.90 min).
Higher optimal FVC and FEV1 values in the intervention group.
Lower post-procedure anxiety scores in the intervention group.
Fewer mild procedure-related adverse events in the intervention group.
Guideline-Based Recommendations
Diagnosis
Methacholine bronchial challenge test (MBCT) is recommended for documenting airway hyperresponsiveness in suspected cough-variant asthma.
Management
Integrate COMFORT-based communication and respiratory training prior to MBCT.
Monitoring & Follow-up
Assess first-attempt success rates and spirometric maneuver quality.
Risks
Monitor for procedure-related anxiety and adverse events during MBCT.
Patient & Prescribing Data
Adults with suspected cough-variant asthma undergoing MBCT.
Empathetic communication and mechanical training can enhance test performance.
Clinical Best Practices
Utilize COMFORT-based communication strategies.
Incorporate mechanical respiratory training before MBCT.
Ensure patient understanding of test procedures to reduce anxiety.
Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.
